Cancer R&D 2024 has wrapped up successfully. We’re grateful for your interest and interaction with Alfa Cytology. We’re eager to continue providing our expertise in cancer drug development. Let’s look back on these memorable moments!

Neural Recombinant Proteins

Neural Recombinant Proteins

Recombinant human BDNF protein, His

CAT#: NRP-N001

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NSE protein, C-His

CAT#: NRP-N002

Keywords: Neural recombinant proteins

Inquiry

Recombinant human PGP9.5 protein, His

CAT#: NRP-N003

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NF-L protein, C-His

CAT#: NRP-N004

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NF-L protein, N-His

CAT#: NRP-N005

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NF-H protein, N-His

CAT#: NRP-N006

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NGF-β protein, C-His

CAT#: NRP-N007

Keywords: Neural recombinant proteins

Inquiry

Recombinant human AD7c-NTP protein, His

CAT#: NRP-N008

Keywords: Neural recombinant proteins

Inquiry

Recombinant human AD7c-NTP protein, GST

CAT#: NRP-N009

Keywords: Neural recombinant proteins

Inquiry

Recombinant human NeuN protein, GST & His

CAT#: NRP-N010

Keywords: Neural recombinant proteins

Inquiry

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

First
1
2

Alfa Cytology provides its clients with one-stop solutions to accelerate therapeutic discovery and development of brain tumors.

By Disease

Craniopharyngioma

Schwannoma (neuroma)

Pituitary Tumors

Choroid Plexus Tumors

By Molecule Type

Small Molecule Drug

Therapeutic Antibody

Immune Cell Therapy

Oncolytic Virotherapy

Vaccine Development

Contact Us

Copyright © 2024 Alfa Cytology. All rights reserved.